|
?:authorAffiliation
|
-
[\'Owlstone Medical Ltd., Cambridge, Cambridgeshire, UK.\', \'Department of Pharmacology and Toxicology, Maastricht University, Maastricht, The Netherlands.\', \'inBiome B.V., Amsterdam, The Netherlands.\', \'Cambridge Clinical Laboratories Ltd., Cambridge, Cambridgeshire, UK.\', \'Cambridge University Hospitals NHS Foundation Trust, Addenbrooke\'s Hospital, Cambridge, UK.\', \'Department of Medicine, Addenbrooke\'s Hospital, Cambridge, UK.\', \'University of Cambridge, Cambridge, UK.\', \'Pulmonology, OLVG, Amsterdam, The Netherlands.\', \'Department of Medical Microbiology, Maastricht University Medical Center, Care and Public Health Research Institute (Caphri), Maastricht, The Netherlands.\', \'Repiratory Department, CHU Liège, Liège, Belgium.\', \'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.\', \'Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.\', \'Department of Experimental and Clinical Biomedical Sciences \'Mario Serio\', University of Florence, Florence, Italy.\', \'Interventional Pulmonology Unit, Careggi University Hospital, Florence, Italy.\', \'Owlstone Medical Ltd., Cambridge, Cambridgeshire, UK. marc.vanderschee@owlstone.co.uk.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}